3 citations
,
January 2022 in “Journal of Infection” Some early COVID-19 mutations in patients predicted future common virus mutations.
February 2026 in “Journal of Thoracic Disease” Long COVID is a big health problem needing more research and better treatments.
October 2025 in “Diseases” Long COVID causes lasting symptoms in many body systems, needing more research for better treatments.
38 citations
,
May 2021 in “International Journal of Infectious Diseases” Low testosterone may indicate severe COVID-19 in men.
1 citations
,
December 2022 in “BMC Public Health” Long-term effects of COVID-19 can vary over time and are more likely in certain age and gender groups, while race, income, and education levels have little to no impact. Ongoing medical care is needed due to potential complications.
9 citations
,
September 2023 in “Viruses” The XBB lineage of the Omicron variant spread rapidly in Southeastern Wisconsin.
3 citations
,
February 2023 in “Journal of Infection and Public Health” More symptoms during initial COVID infection increase the risk of long-term effects.
42 citations
,
April 2021 in “Pharmaceuticals” Five FDA-approved drugs may help block COVID-19 virus entry.
15 citations
,
March 2023 in “BioMed” MIS-A is a severe complication after COVID-19, mostly in young black males, needing more research and awareness.
10 citations
,
March 2022 in “Healthcare” Mineralocorticoid receptor antagonist therapy does not significantly reduce mortality in COVID-19 patients.
2 citations
,
August 2024 in “Heliyon” Metformin may help mild COVID-19 cases, while Oseltamivir, Tamoxifen, and Dexamethasone are suggested for severe cases.
12 citations
,
November 2021 in “Journal of Clinical Medicine” Kidney transplant patients who had COVID-19 experienced a significant drop in their quality of life due to long-lasting symptoms.
1 citations
,
January 2021 in “Research Square (Research Square)” Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.
6 citations
,
October 2024 in “npj Digital Medicine” Long-COVID causes more health issues after COVID-19, varying by age, sex, and infection wave.
January 2024 in “Pediatria Polska” Long-COVID symptoms in children after MIS-C are similar across different COVID-19 variants, with older age being a key factor.
7 citations
,
July 2020 in “Journal of The American Academy of Dermatology” Skin symptoms linked to COVID-19 are hard to confirm, and more testing is needed to identify which are truly caused by the virus.
6 citations
,
March 2022 in “Frontiers in drug discovery” Some small molecule antivirals show promise against COVID-19, but more research is needed to understand and improve them.
69 citations
,
January 2021 in “Journal of Biological Chemistry” Plant-derived amino acids can help develop new antimicrobial drugs.
7 citations
,
May 2022 in “The Journal of Dermatology” Hair loss is a frequent long-term effect of COVID-19, and oral minoxidil is the most common effective treatment.
July 2024 in “Dermatology Practical & Conceptual” COVID-19-related hair loss may have unique features compared to hair loss from other causes.
123 citations
,
May 2020 in “Drug Development Research” Men's sensitivity to male hormones might affect how severe COVID-19 gets for them.
71 citations
,
April 2020 in “Journal of Cosmetic Dermatology” Genetic differences may affect COVID-19 deaths; anti-androgens could be potential treatment.
49 citations
,
January 2021 in “Journal of The European Academy of Dermatology and Venereology” Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
21 citations
,
May 2021 in “Prostate Cancer and Prostatic Diseases” COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.
2 citations
,
July 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” COVID-19 causes more taste, smell, hair, memory, and concentration issues than other respiratory infections.
COVID-19 can cause significant hair loss.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
March 2022 in “Journal of Clinical Case Studies Reviews & Reports” COVID-19 can cause or worsen skin conditions and might show early signs of infection.
June 2020 in “Journal of Dermatological Treatment” Use telemedicine and strict hygiene for safe hair and scalp treatments during COVID-19.
8 citations
,
February 2022 in “Frontiers in Medicine” COVID-19 may trigger severe skin flare-ups in people with autoimmune conditions like lupus.